Sensei Biotherapeutics to Participate in the Canaccord Genuity Horizons in Oncology Virtual Conference

Core Insights - Sensei Biotherapeutics, Inc. is a clinical stage biotechnology company focused on developing next-generation therapeutics for cancer patients [2] - The company will participate in the Canaccord Genuity Horizons in Oncology Virtual Conference on April 7, 2025, with CEO John Celebi as a panelist [1] Company Overview - Sensei Biotherapeutics utilizes its TMAb™ platform to create conditionally active therapeutics that target the tumor microenvironment [2] - The lead product candidate, solnerstotug, is designed to block the VISTA checkpoint selectively in low pH tumor environments, which helps activate T cells against tumors [2]